Your browser doesn't support javascript.
loading
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Mian, Afsar Ali; Haberbosch, Isabella; Khamaisie, Hazem; Agbarya, Abed; Pietsch, Larissa; Eshel, Elizabeh; Najib, Dally; Chiriches, Claudia; Ottmann, Oliver Gerhard; Hantschel, Oliver; Biondi, Ricardo M; Ruthardt, Martin; Mahajna, Jamal.
Afiliación
  • Mian AA; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  • Haberbosch I; Center for Regenerative Medicine and Stem Cell Research, Aga Khan University, Karachi, Pakistan.
  • Khamaisie H; Department of Internal Medicine II, Goethe University, Frankfurt, Germany.
  • Agbarya A; Department of Nutrition and Natural Products, Migal-Galilee Technology Center, PO Box 831, 11016, Kiryat Shmona, Israel.
  • Pietsch L; Oncology Department, Bnai Zion MC, Haifa, Israel.
  • Eshel E; Department of Internal Medicine I, Clinic of Goethe University, Frankfurt, Germany.
  • Najib D; German Cancer Consortium (DKTK), Frankfurt, Germany.
  • Chiriches C; Hematology Institute, Ziv Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Zfat, Israel.
  • Ottmann OG; Hematology Institute, Ziv Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Zfat, Israel.
  • Hantschel O; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  • Biondi RM; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  • Ruthardt M; Swiss Institute for Experimental Cancer Research, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
  • Mahajna J; Medical Biochemistry and Pharmacology Center, Institute for Physiological Chemistry, Philipps-University, Marburg, Germany.
Ann Hematol ; 100(8): 2023-2029, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34110462
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas Proto-Oncogénicas c-abl / Proteínas de Fusión bcr-abl / Leucemia-Linfoma Linfoblástico de Células Precursoras / Crizotinib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas Proto-Oncogénicas c-abl / Proteínas de Fusión bcr-abl / Leucemia-Linfoma Linfoblástico de Células Precursoras / Crizotinib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Alemania